TICAGRELOR CAS no 274693-27-5

$1 - 100 /Gram

Min. Order:

1 Gram

Contact Now

Product Description

Overview

Packaging & Delivery

Selling Units:: Gram

The antiplatelet agglutination drug ticagrelor is a new type of antiplatelet agglutination drug, which was successfully developed by AstraZeneca in the United States. It is the world's first reversible combined oral P2Y12 adenosine diphosphate receptor antagonist. The drug can reversibly act on the purinoceptor2 (P2) subtype P2Y12 on vascular smooth muscle cells (VSMC), without metabolic activation, and has a significant inhibitory effect on platelet aggregation caused by adenosine diphosphate (ADP) , And the effect is rapid after oral use, which can effectively improve the symptoms of patients with acute coronary heart disease. Unlike thienopyridines, ticagrelor is a reversible inhibitor of P2Y12 receptors, so it is especially suitable for patients who need to undergo anticoagulation therapy before undergoing surgery.

Product Categories : API Intermediates > Ticagrelor Intermediate

Hot Products

Email to this supplier

*Subject:
*To:

Ms. Lily
*Email:
*Message:

Your message must be between 20-8000 characters